213 related articles for article (PubMed ID: 27376425)
21. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J
J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
[TBL] [Abstract][Full Text] [Related]
22. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
Jenkins PJ; Akker S; Chew SL; Besser GM; Monson JP; Grossman AB
Clin Endocrinol (Oxf); 2000 Dec; 53(6):719-24. PubMed ID: 11155094
[TBL] [Abstract][Full Text] [Related]
23. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension.
Melmed S; Cook D; Schopohl J; Goth MI; Lam KS; Marek J
Pituitary; 2010; 13(1):18-28. PubMed ID: 19639415
[TBL] [Abstract][Full Text] [Related]
24. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
Feelders RA; Hofland LJ; van Aken MO; Neggers SJ; Lamberts SW; de Herder WW; van der Lely AJ
Drugs; 2009 Nov; 69(16):2207-26. PubMed ID: 19852525
[TBL] [Abstract][Full Text] [Related]
25. [Outcome of somatostatin analogue treatment in acromegaly].
Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.
Chanson P; Leselbaum A; Blumberg J; Schaison G
Pituitary; 2000 May; 2(4):269-76. PubMed ID: 11081148
[TBL] [Abstract][Full Text] [Related]
27. Results of a two-year treatment with slow release lanreotide in acromegaly.
Cannavò S; Squadrito S; Curtò L; Almoto B; Vieni A; Trimarchi F
Horm Metab Res; 2000 Jun; 32(6):224-9. PubMed ID: 10898551
[TBL] [Abstract][Full Text] [Related]
28. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly.
Attanasio R; Baldelli R; Pivonello R; Grottoli S; Bocca L; Gasco V; Giusti M; Tamburrano G; Colao A; Cozzi R
J Clin Endocrinol Metab; 2003 Nov; 88(11):5258-65. PubMed ID: 14602759
[TBL] [Abstract][Full Text] [Related]
29. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
[TBL] [Abstract][Full Text] [Related]
30. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).
Baldelli R; Colao A; Razzore P; Jaffrain-Rea ML; Marzullo P; Ciccarelli E; Ferretti E; Ferone D; Gaia D; Camanni F; Lombardi G; Tamburrano G
J Clin Endocrinol Metab; 2000 Nov; 85(11):4099-103. PubMed ID: 11095439
[TBL] [Abstract][Full Text] [Related]
31. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.
Casarini AP; Pinto EM; Jallad RS; Giorgi RR; Giannella-Neto D; Bronstein MD
J Endocrinol Invest; 2006 Oct; 29(9):826-30. PubMed ID: 17114915
[TBL] [Abstract][Full Text] [Related]
32. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.
Kendall-Taylor P; Miller M; Gebbie J; Turner S; al-Maskari M
Pituitary; 2000 Oct; 3(2):61-5. PubMed ID: 11141697
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic evaluation of lanreotide.
Hu M; Tomlinson B
Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1301-12. PubMed ID: 20716034
[TBL] [Abstract][Full Text] [Related]
34. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
35. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
36. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
[TBL] [Abstract][Full Text] [Related]
37. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
[TBL] [Abstract][Full Text] [Related]
38. Pituitary tumours: acromegaly.
Chanson P; Salenave S; Kamenicky P; Cazabat L; Young J
Best Pract Res Clin Endocrinol Metab; 2009 Oct; 23(5):555-74. PubMed ID: 19945023
[TBL] [Abstract][Full Text] [Related]
39. Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome.
Colao A; Pivonello R; Di Somma C; Tauchmanovà L; Savastano S; Lombardi G
Clin Endocrinol (Oxf); 2007 May; 66(5):714-22. PubMed ID: 17388794
[TBL] [Abstract][Full Text] [Related]
40. [Advances in the treatment of acromegaly].
Krysiak R; Okopień B; Marek B
Pol Merkur Lekarski; 2008 Jan; 24(139):59-65. PubMed ID: 18634256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
